BeyondSpring Inc. (BYSI)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BeyondSpring Inc. (“BeyondSpring” or the “Company”) (NASDAQ: BYSI). The investigation concerns whether BeyondSpring and certain of its officers and/or directors have violated federal securities laws.
On December 1, 2021, BeyondSpring issued a press release “announc[ing] it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its present form.” BeyondSpring stated that “[t]he FDA’s CRL indicated that the results of the single registrational trial (106 Phase 3) was not sufficiently robust to demonstrate benefit and that a second well controlled trial would be required to satisfy the substantial evidence requirement to support the CIN indication.” On this news, BeyondSpring’s stock price fell sharply during intraday trading on December 1, 2021.
If you are aware of any facts relating to this investigation or purchased BeyondSpring shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.